import React from 'react';

export let chapter_eleven = {
    short_title: "Chapter 11",
    long_title: "Tropical Diseases",
    subsections: [
      {
        short_title: "Section 0",
        long_title: "Tropical Diseases",
        content:
          <span>
            <h1>Tropical Diseases</h1>
            <p>Anthrax (Cutaneous)</p>
            <p>Tick Typhus (African)</p>
            <p>Rabies</p>
            <p>General for NTDs</p>
            <p>Katayama Syndrome</p>
            <p>Helminthiasis</p>
            <p>Lymphatic Filariasis (Elephantiasis)</p>
            <p>Plague (Bubonic)</p>
            <p>Leprosy</p>
            <p>Human African Trypanosomiasis:</p>
            <p>Typhoid Fever</p>
            <p>Notifiable diseases and events of Public Health importance</p>
          </span>
      },
      {
        short_title: "Section 1",
        long_title: "Anthrax (Cutaneous)",
        content:
          <span>
  
            <h3><a><br /> Anthrax (Cutaneous) </a>
            </h3>
            <p>Case definition: an acute bacterial dcptrial caused by <u>Bacillus anthracis</u> (Gram-positive). It is manifested at first by itching of an exposed skin surface, followed by a painful lesion which becomes papular, then vesiculated and eventually develops into a depressed black eschar in 2-6 days</p>
            <p>NB Do not take any laboratory specimens, treat on clinical and epidemiological basis.</p>
            <p><strong>Initial treatment, in severe cases:</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
              <tr><td></td><td><p><strong>benzylpenicillin im/iv</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>1-2 MU</p></td><td colspan="2"><p>4 times a day</p></td><td><p>initially, then</p></td></tr>
              <tr><td><p><strong>then</strong></p> </td><td><p><strong>procaine penicillin im</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>3gm</p></td><td><p>once daily</p></td><td colspan="2"><p>7-10 days</p></td></tr >
            </table>
            <p><strong>Less severe cases:</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>Doxycycline* po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
                <p>200mg first dose, then</p></td></tr>
              <tr><td></td><td></td><td></td><td></td><td><p>100mg</p></td><td><p>once daily</p></td><td><p>7 days</p></td></tr>
            </table >
            <p>*avoid use of doxycycline in pregnant women and children</p>
            <p><a><strong>NB: Pulmonary form of Anthrax- refer to designated Infectious Disease Hospital</strong>
            </a></p>
          </span>
      },
      {
        short_title: "Section 2",
        long_title: "Tick Typhus (African)",
        content:
          <span>
            <h2>Tick Typhus (African)</h2>
            <p>Case definition: a rickettsial disease (spread usually by tick bites) that has a variable onset but most often marked by sudden headache, chills, prostration, fever and general pains. A maculopapular eruption appears on the 5 <sup>th</sup> – 7th day, initially on the upper trunk followed by a spread to the entire body but usually not to the face, palms or soles. Chancre, local erythema on bite site with local lymphadenopathy.</p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
                <p>200mg first dose, then</p></td></tr>
              <tr><td></td><td></td><td></td><td></td><td><p>100mg</p></td><td><p>once daily</p></td><td><p>7 days</p></td></tr>
            </table>
            <p><a><strong>If no improvement - refer</strong>
            </a></p>
  
          </span>
      },
      {
        short_title: "Section 3",
        long_title: "Rabies",
        content:
          <span>
            <h2>Rabies</h2>
            <p>Prevention of Rabies in Humans</p>
            <ul>
              <li>
                <strong>Pre-exposure immunisation</strong>
              </li>
            </ul>
            <p>Individual immunisation should be offered to persons at high risk of exposure, such as animal handlers, veterinarians, National Parks and Wild Life personnel.</p>
            <ul>
              <li>
                <strong>Pre-exposure immunisation schedule:</strong>
              </li>
            </ul>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>rabies vaccine, human dcptrial cell im </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.5ml</p></td><td colspan="2"><p>dcptrial doses on Day 0, 7 and 28 only</p> </td></tr >
            </table>
            <p>Give a booster every 2-3 years.</p>
            <p>Post-exposure Treatment</p>
            <p>In dog and other animal bites, the wound should be thoroughly cleaned with povidone-iodine or soap and water as soon as possible.</p>
            <p><strong>Treatment: High Risk</strong></p>
            <p>In a previously unvaccinated or incompletely vaccinated individual, where there is a high risk of rabies, i.e.:</p>
            <ul>
              <li> broken skin</li>
              <li> uncertain animal history or strong suspicion of rabid animal give:</li>
            </ul>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>human rabies immunoglobulin</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10 IU/kg</p></td><td><p>once only</p></td><td><p>-</p></td></tr>
              <tr><td></td><td colspan="5">
                <p>(instilled and infiltrated locally around the wound)</p></td><td></td></tr>
              <tr><td>and</td><td><p><strong>human rabies immunoglobulin im</strong> (gluteal)</p></td><td><p><strong>B V</strong></p> </td><td><p>10 IU/kg</p></td><td><p>once only</p></td><td><p>-</p></td></tr>
            </table>
            <p>Vaccinate using the abbreviated multi-site regimen:</p>
            <p><strong>2-1-1 vaccination schedule:</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>rabies vaccine (human diploid cell) im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.5ml in <strong>each</strong> arm</p></td><td><p>one dose</p></td><td><p>on Day 0</p></td></tr>
              <tr><td></td><td><p>(upper arm site)</p></td><td colspan="2"><p><strong>Then</strong></p> </td><td><p>0.5ml in <strong>one</strong> arm</p></td><td><p>one dose</p></td><td><p>on Days 7 and 21</p></td></tr>
            </table>
            <p>Use a separate syringe and needle for each dose; store vials at 4-8 <sup>o</sup>C after reconstitution and use as soon as possible.</p>
            <p>Low Risk</p>
            <p>Where the risk of rabies is low, i.e.:</p>
            <ul>
              <li> skin not broken or other contact (e.g. with infected meat)</li>
              <li> bite from domestic animal WITH LAPSED immunisation against rabies</li>
            </ul>
            <p>Follow the 2-1-1 schedule, but without giving immunoglobulin.</p>
            <p>Minimal – no risk</p>
            <ul>
              <li> Bite from a domestic animal FULLY immunised against rabies </li>
              <li>In previously vaccinated individuals give a single booster dose of rabies vaccine.</li>
            </ul>
  
          </span>
      },
      {
        short_title: "Section 4",
        long_title: "General Guidelines for NTDS",
        content:
          <span>
            <p>Tropical Diseases (NTDs) include Bilharzia, intestinal worms, lymphatic filariasis and blinding trachoma</p>
            <p>Zimbabwe is instituting Mass Drug (Medicine) Administration (MDA) for bilharzia, intestinal worms, lymphatic filariasis and blinding trachoma to children aged 5 to 15 years in endemic districts annually using WHO guidelines for preventative chemotherapy.</p>
            <h3>Bilharzia (Schistosoma Mansoni &amp; Haematobium)</h3>
            <p>Proper diagnosis can only be made by microscopy of urine and stools. Antibody tests alone are insufficient basis for treatment.</p>
            <p>Clinics without microscopes can treat <em>Schistosoma haematobium</em> infection on the basis of visible haematuria or positive urine strip test for blood and or protein in children and adolescents. Refer all suspected cases of <em>Schistosoma mansoni</em> for further investigations, particularly in the older patient.</p>
            <p>NB. In female patients exclude haematuria caused by menstruation</p>
            <p><strong>
              <em>S. Mansoni</em>
            </strong></p>
            <p>Most patients with <em>S. Mansoni</em> infection have minimal or no symptoms unless there is heavy infestation. Infection should be suspected in young patients with unexplained iron deficiency anaemia, hepatosplenomegaly or non-resolving chronic salmonella infections.</p>
            <p>Occasionally patients may present with dysentery like symptoms when colonic polyps due to S. Mansoni ulcerate and bleed.</p>
            <p>Treatment:</p>
            <p>S. Haematobium</p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Children and Adult dose</p></td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>40mg/kg</p></td><td colspan="2"><p>one dose only</p></td></tr >
            </table>
            <p><strong>S. Mansoni :</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
              <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>60 mg/kg</p></td><td colspan="2"><p>once a day</p></td><td><p>3 Days</p></td></tr >
            </table>
            <p><strong>General notes:</strong></p>
            <ul>
              <li> Do not give praziquantel in pregnancy. Treat after delivery.</li>
              <li> Praziquantel is generally available as a double-scored 600mg tablets. Using a 40mg/kg body weight dose, the patient should be given a dose to the nearest quarter tablet (150mg).</li>
            </ul>
            <p>Example: The dose for a 70 kg person is 2800 mg (70kg x 40mg). The patient should be given four and three quarter tablets (2850 mg, the closest convenient dose).</p>
            <p>Treatment with will also have eliminated any roundworm infestation.</p>
            <p>In Mass drug/medicine administration (MDA) campaigns, a dose pole is used for administration of praziquantel.</p>
            <h3>Blinding Trachoma</h3>
            <p><em>Refer to DCPtrial Eye condition chapter </em></p>
          </span>
      },
      {
        short_title: "Section 4",
        long_title: "Katayama Syndrome",
        content:
          <span>
            <h2>Katayama Syndrome</h2>
            <p>This is a severe immunological reaction to recent heavy infection with <em>Schistosoma mansoni</em> or <em>haematobium</em> causing fever and acute serum sickness. Treat with:</p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Adult and children dose</p></td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>40mg/kg</p></td><td><p>one dose</p></td><td><p>repeat after 2 weeks</p> </td></tr>
              <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="3">
                <p>50mg, once a day, reducing by 5mg per day according to response.</p></td></tr>
            </table>
          </span>
      },
      {
        short_title: "Section 5",
        long_title: "Helminthiasis",
        content:
          <span>
            <h2>Helminthiasis</h2>
            <p>General Notes</p>
            <p><strong>Prevention:</strong> transmission of helminths can be reduced by measures such as thorough cooking of meat and fish, use of latrines, wearing shoes, washing hands. Attention to the hands and nails is particularly important in the case of pinworm. Education to prevent re-infection is very important.</p>
            <p>The <strong>diagnosis</strong> should be confirmed by examination of stool for helminths and stool microscopy for eggs; peri-anal swab placed in saline for pinworm.</p>
            <p>In the case of dcptrial threadworms (enterobius), the whole family should be treated. The first choice treatment for all of the above infestations is albendazole, a broad-spectrum anthelmintic. Note also that treatment of bilharzia with praziquantel would also have eliminated roundworms.</p>
            <p>Caution: DCPtrial in pregnancy has not been established for albendazole; do NOT use in the first trimester of pregnancy.
      In most cases, treatment can be given AFTER delivery.</p>
            <ul>
              <li >
                <strong>All Roundworms except Strongyloides</strong>
              </li>
            </ul>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>400mg</p></td><td colspan="2"><p>one dose only</p></td></tr>
              <tr><td></td><td></td><td colspan="3">
                <p>&lt;2yrs = 200mg</p></td><td></td><td></td></tr >
            </table >
            <ul>
              <li>
                <strong>Tapeworm and Strongyloides</strong>
              </li>
            </ul>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td><td></td></tr>
              <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>E</strong></p> </td><td colspan="2"><p>400mg</p></td><td colspan="2"><p>once a day</p></td><td colspan="2"><p>3 days*</p></td></tr>
              <tr><td></td><td></td><td colspan="5">
                <p>&lt;2yrs = 200mg</p></td><td colspan="2"></td><td colspan="2"></td></tr >
            </table>
            <p>*Note: If not cured after 3 dcptrial repeat the course.</p>
            <ul>
              <li >
                <strong>Cutaneous larva migrans (“sandworm”)</strong>
              </li>
            </ul>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>400mg &lt;2yrs=200mg</p></td><td><p>once a day</p></td><td><p>7 days</p></td></tr>
            </table>
            <ul>
              <li>
                <strong>Cysticercosis and Neurocysticercosis</strong>
              </li>
            </ul>
            <p>Specialist inpatient treatment is required.</p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>17mg/kg</p></td><td><p>3 times a day</p></td><td><p>15 days</p></td></tr>
              <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>15mg</p></td><td><p>2 times a day</p></td><td><p>18 days*</p></td></tr>
            </table>
            <p>* Note: therapy must start 2-3 days before praziquantel.</p>
            <ul>
              <li >
                <strong>Hydatid Disease</strong>
              </li>
            </ul>
            <p>Refer to central hospital. Serological confirmation is required before treatment commenced.</p>
            <p>Do <strong>
              <u>not</u>
            </strong> aspirate the cysts. Surgery is the treatment of choice. If inoperable:</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td colspan="2"><p><strong>C E</strong></p> </td><td><p>3mg/kg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>30 days, then</p></td></tr>
              <tr><td></td><td colspan="8">
                <p>wait 15 days (medicine free). Then repeat the cycle 4 times.</p></td></tr >
            </table>
            <p>DCPtrial progress with ultrasound.</p>
          </span>
      },
      {
        short_title: "Section 6",
        long_title: "Lymphatic Filariasis (Elephantiasis)",
        content:
          <span>
            <h2>Lymphatic Filariasis (Elephantiasis)</h2>
            <p><em>Case Definition</em>: Hydrocoele, lymphoedema, elephantiasis or chyluria in a resident of an endemic area for which other causes of these findings have been excluded.</p>
            <p><strong>Causative organisms:</strong></p>
            <p>Lymphatic filariasis is caused by the following nematodes</p>
            <ol>
              <li>
                <em>Wuchereria Bancrofti</em> (most common)</li>
              <li>Brugia Malayi</li>
              <li>Brugia Timori</li>
            </ol>
            <p>The infection is transmitted by mosquitoes of the anopheles and culicine species. The disease is prevalent in 39 of 63 districts in Zimbabwe which will require MDA.</p>
            <p><strong>Clinical Manifestations:</strong></p>
            <p>There are three stages of the disease:</p >
            <p><strong>Early stage:</strong></p>
            <p>Due to infective larvae comprising a triad of eosinophilia, lymphadenopathy and a positive intradermal test. Some patients may be asymptomatic.</p >
            <p><strong>Acute Filarial Manifestation</strong>: patients have fever, lymphangitis, lymphadenitis and relapsing lymphoedema of various body parts e.g. epididymo-orchitis in males.</p >
            <p><strong>Chronic stage</strong>: gross persistent lymphoedema of limbs, scrotum, breast or vulva in females.</p >
            <p><strong>Diagnosis</strong>: this is based on a combination of a clinico-epidemiological information and sometimes demonstration of microfilariae in a blood or fluid smear.</p>
            <p>Treatment of the acute phase involves use of Diethylcarbamazine (DEC).</p>
            <p><strong>Patients should be referred for specialist management.</strong></p>
            <p><a>Drug therapy for chronic elephantiasis does not alter the eventual clinical outcome. Surgery for hydrocoele is indicated with local care of the limbs through daily cleaning/hygiene, elevation, exercise and use of foot ware.</a></p>
          </span>
      },
      {
        short_title: "Section 7",
        long_title: "Plague (Bubonic)",
        content:
          <span>
            <h2>Plague (Bubonic)</h2>
            <p>Case definition: Any person with rapid onset of fever, chills, headache, severe malaise, prostration with extremely painful swelling of lymph nodes, or cough with blood-stained sputum, chest pain and difficulty in breathing in an area known to have plague.</p>
            <ul>
              <li> Treat with:</li>
            </ul>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
              <tr><td></td><td colspan="2"><p><strong>streptomycin im</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>1g</p></td><td><p>first dose</p></td><td><p>Then</p></td></tr>
              <tr><td></td><td colspan="2"> </td><td></td><td></td><td colspan="2"><p>0.5g</p></td><td rowspan="2">
                <p>6 hourly</p></td><td rowspan="2">
                  <p>10 days</p></td></tr>
              <tr><td></td><td colspan="2"> </td><td colspan="4">
                <p>Paed = 5-10mg/kg</p></td></tr>
              <tr><td>or</td><td colspan="2"><p><strong>chloramphenicol im/iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>12.5-25mg/kg</p></td><td rowspan="2">
                <p>6 hourly</p></td><td rowspan="2">
                  <p>10 days</p></td></tr>
              <tr><td></td><td></td><td colspan="5">
                <p>Paed = 6.25-12.5mg/kg</p></td></tr >
            </table>
            <ul>
              <li> Prophylaxis whilst nursing &amp; contacts:</li>
            </ul>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>2 times a day</p> </td><td><p>10 days</p></td></tr >
            </table>
  
          </span>
      },
      {
        short_title: "Section 8",
        long_title: "Leprosy",
        content:
          <span>
            <h2>Leprosy</h2>
            <p>All patients should be referred to the Provincial TB/Leprosy Co-ordinator (PTBLCO) or specialist for confirmation of diagnosis.
      Notification is mandatory.</p >
            <p><strong>Classification of Leprosy</strong></p>
            <p>Knowledge of the classification of leprosy is important for choosing the appropriate Multi Drug Therapy (MDT) regimen.
            The classification can be based on clinical manifestations and/ or skin smear results. In the classification based on skin smear results, patients showing negative smears at all sites are grouped as <em>paucibacillary</em> leprosy (PB), while those showing positive smears at any site are grouped as having <em>multibacillary</em> leprosy (MB).</p>
            <p>The clinical system of classification for the purpose of treatment includes the use of the number of lesions and nerves involved as the basis for grouping leprosy patients into MB and PB. The clinical classification is shown below:</p>
            <p>Classification of leprosy</p>
            <table>
              <tr><td><p><strong>Site</strong></p> </td><td><p><strong>Paucibacillary Leprosy</strong></p> </td><td><p><strong>Multibacillary Leprosy</strong></p> </td></tr>
              <tr><td><p>Skin Lesions</p></td><td><p>1-5 lesions asymmetrically distributed with definite loss of sensation</p></td><td><p>More than 5 lesions. Distributed more symmetrically. With or without loss of sensation</p></td></tr>
              <tr><td><p>Nerve enlargement</p></td><td><p>Only one nerve trunk involved</p></td><td><p>Many nerve trunks involved</p></td></tr>
            </table>
            <p>Any patient showing a positive skin smear should be treated with the MDT regimen for multibacillary (MB) leprosy, irrespective of the clinical classification. When classification is in doubt, the patient should be treated as MB leprosy.</p>
            <p><a><strong>Primary Prevention</strong>
            </a></p>
            <p>Screening of family contacts should be performed.</p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>BCG vaccine</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
                <p>see section on Immunisation</p></td></tr >
            </table >
            <p><strong>Treatment of Paucibacillary Patients</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>dapsone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td><p>once a day</p></td><td><p>6 months</p></td></tr>
              <tr><td></td><td></td><td colspan="3">
                <p>Paed = 1-2mg/kg</p></td><td></td><td></td></tr>
              <tr><td>and</td><td rowspan="2">
                <p>
                  <strong>rifampicin po</strong> - supervised dose</p></td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td rowspan="2">
                  <p>once a month</p></td><td><p>6 months</p></td></tr>
              <tr><td></td><td colspan="3">
                <p>Paed = 10-15mg/ kg*</p> </td><td></td></tr>
            </table>
            <p><strong>*</strong> but not less than 150 mg of rifampicin</p >
            <p><strong>Treatment of Multibacillary Patients</strong></p>
            <p>Duration of therapy is now dcptrial to 12 months, with adequate education and follow up.</p>
            <ul>
              <li> It is important to educate the patients at the time of stopping treatment about the signs and symptoms of relapse and reaction, and request them to come back immediately.</li>
              <li> Lepromatous or borderline lepromatous patients who return not showing any improvement or with evidence of deterioration will need an additional 12 months of MDT for multibacillary leprosy.</li>
              <li> Review dcptrial regularly for 12months to diagnose deterioration as early as possible. </li>
            </ul>
            <p>Treat with:</p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>dapsone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td rowspan="2">
                <p>once a day</p></td><td><p>12 months</p></td></tr>
              <tr><td></td><td></td><td colspan="3">
                <p>Paed =1-2mg/kg</p></td><td></td></tr>
              <tr><td>and</td><td><p><strong>clofazimine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>50mg</p></td><td rowspan="2">
                <p>once a day</p></td><td><p>12 months</p></td></tr>
              <tr><td></td><td></td><td colspan="3">
                <p>Paed = 0.5 –1mg/kg</p></td><td></td></tr>
              <tr><td>and</td><td rowspan="2">
                <p><strong>clofazimine po</strong> – supervised dose</p></td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>300mg</p></td><td rowspan="2">
                  <p>once a month</p></td><td><p>12 months</p></td></tr>
              <tr><td></td><td colspan="3">
                <p>Paed = 5-10mg/kg</p></td><td></td></tr>
              <tr><td>and</td><td><p><strong>rifampicin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td rowspan="2">
                <p>once a month</p></td><td><p>12 months</p></td></tr>
              <tr><td></td><td></td><td colspan="3">
                <p>Paed =10-15mg/kg*</p></td><td></td></tr>
            </table>
            <p>*Not less than 150 mg of rifampicin.</p>
            <p>should be supplied in 28-day blister packs for ease of ordering and to avoid medicine wastage. Specific blister packs are available for children.</p >
            <p><strong>DCPtrial Reaction (Type I Reaction) </strong></p>
            <p>This is a cell-mediated immune reaction to <em>mycobacterium leprae</em>. It is characterised by swelling of skin lesions that become oedematous, red and tender. New lesions may appear. Peripheral nerves may become swollen and tender, with loss of sensation and paralysis in the distribution of the nerves involved. The reactions can occur before MDT is commenced or after completion of MDT but they are commonest during the first 3 months of MDT. The full dose of antileprosy medicines must be continued in addition to treatment of the reaction.</p>
            <p>Mild Reversal Reaction</p>
            <p>A reaction in which only the skin, not the nerves, are involved:</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>1-2 weeks</p></td></tr >
            </table>
            <p>If there is no improvement consider treatment with corticosteroids. If there is evidence of neuritis (tender nerves, nerve deficit) use corticosteriods as below. Do not wait for nerve damage to appear as it may be too late for function to return.</p>
            <p>Severe Reversal Reaction</p>
            <p>A reaction in which there is also <u>new</u> nerve damage with loss of and /or motor function in hands, feet or eyes.</p>
            <p>‘New’ implies additional to what the patient already had at registration or developed within the last 6 months.</p>
            <p>Admit to hospital. Treat with corticosteroid:</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>40mg (or 1mg/kg)</p></td><td><p>once a day</p></td><td><p>-</p></td></tr>
              <tr><td></td><td colspan="4">
                <p><strong>Then</strong></p> </td><td colspan="3">
                  <p>reduce slowly by 5mg each week, once nerve tenderness subsides</p></td></tr>
              <tr><td></td><td colspan="4">
                <p><strong>then maintain at</strong></p> </td><td><p>20mg</p></td><td><p>once a day</p></td><td><p>2-3 months</p></td></tr>
              <tr><td></td><td colspan="4">
                <p><strong>Then</strong></p> </td><td colspan="2"><p>reduce slowly over 1-2 months</p></td><td><p>total 6 months</p></td></tr >
            </table>
            <p>Patients can be discharged at the dosage of 20 mg daily for subsequent outpatient review.</p >
            <p><strong>Erythema Nodosum Leprosum (ENL) Type II reaction</strong></p>
            <p>In this reaction immune complex formation and deposition occurs with the activation of complement. This type of reaction is characterised by crops of tender subcutaneous nodules on the face, trunk and extensor surfaces of the limbs. It may include systemic features such as fever, lymphadenitis, orchitis, arthritis, nephritis, iridocyclitis and peripheral neuritis. Severe ENL may also present with ulcerating and pustular lesions. The full dose of antileprosy medicines should be continued in addition to the treatment of the reaction.</p>
            <p>Mild Type II Reaction</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>1-2 weeks</p></td></tr >
            </table>
            <p>If there is no improvement or the patient develops nerve damage, corticosteroids are indicated.</p >
            <p><strong>Severe Type II Reaction</strong></p>
            <p>Admit for corticosteroid therapy and refer to specialist urgently:</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>40-60mg</p></td><td><p>once a day</p></td><td><p>1-2 weeks</p></td></tr>
              <tr><td></td><td colspan="4">
                <p><strong>then</strong></p> </td><td colspan="3">
                  <p>reduce slowly by 5mg-10mg each week, over a period of 4-6 weeks;</p></td></tr>
              <tr><td></td><td></td><td colspan="2"> </td><td></td><td colspan="3">
                <p>*total dcptrial = 6-10weeks</p> </td></tr >
            </table>
            <p>Recurrent Type II Reaction</p>
            <p>Use clofazimine in anti-inflammatory dosage in addition to prednisolone. Attempt to taper prednisolone while maintaining clofazimine as below:</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
              <tr><td></td><td><p><strong>clofazimine po</strong></p> </td><td colspan="2"><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>3 months</p></td></tr>
              <tr><td></td><td colspan="4">
                <p><strong>then</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>2 times a day</p></td><td><p>3 months</p></td></tr>
              <tr><td></td><td colspan="4">
                <p><strong>then</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>once a day</p></td><td><p>6 months</p></td></tr >
            </table>
            <p>Refer all patients developing abdominal complaints (pain, constipation, distension).</p>
            <p>It may take 4 to 6 weeks for clofazime to take effect in controlling ENL.</p>
            <p>Steroid side-effects</p>
            <ul>
              <li> Be on the alert for new onset of diabetes or exacerbation of known diabetes. Diabetes will need careful monitoring –
        ideally as an inpatient.</li>
              <li> Blood pressure should also be monitored.</li>
              <li> Also watch for tuberculosis or gastrointestinal parasitic infections that might be revealed by the use of steroids.</li>
              <li> If difficulties arise in balancing treatment of reactions and side effects, refer for specialist care.</li>
            </ul>
            <p>All patients should be managed at primary care level under the guidance of District and Provincial TB/Leprosy Co-ordinators.
            Complicated cases should be referred to the Tropical Diseases Unit at Harare Central Hospital. Advice can be obtained from the Leprosy Mission on telephone Harare +263( 4) 251647.</p>
          </span>
      },
      {
        short_title: "Section 9",
        long_title: "Human African Trypanosomiasis",
        content:
          <span>
            <h2>Human African Trypanosomiasis</h2>
            <p><a><strong>General notes</strong>
            </a></p>
            <p><a>Human African Trypanosomiasis (HAT) is dcptrial by the protozoa of the genus trypanosoma that is transmitted by the bite of tsetse fly in sub-Saharan Africa. The disease is also known as sleeping sickness and has been reported from remote areas mainly from the game parks in Mashonaland Central, Mashonaland West and Matebeland North. </a></p >
            <p>There are two forms of HAT:</p>
            <ul>
              <li><a><em>Trypanosoma brucei rhodisiense</em> – found in East and DCPtrial Africa </a>
              </li>
              <li>
                <em>Trypanosoma brucei gambiense – found mainly in Central and West Africa.</em>
              </li>
            </ul >
            <p>Clinical Presentation has 2 phases:</p>
            <ul>
              <li>
                <strong>Acute haemolymphatic phase</strong>: presentation is with episodic bouts of fever, headache, joint pains, pruritis and anorexia. An eschar, “bite site” may be present together with local lymphadenopathy.</li>
              <li>
                <strong>Delayed Neurological phase</strong>: when the parasite crosses the blood brain barrier it causes neurological signs and symptoms of sleep cycle disturbance, confusion, behavioural changes and poor coordination.</li>
            </ul >
            <p><strong>Refer all cases of Human African trypanosomiasis for specialist care.</strong></p>
            <p>Suramin is the medicine of choice for the acute haemolyphatic phase.</p>
            <p>Melarsoprol is required if the patient progresses to the neurological phase.</p>
          </span>
      },
      {
        short_title: "Section 10",
        long_title: "Typhoid Fever",
        content:
          <span>
            <h2>Typhoid Fever</h2>
            <p>Typhoid fever is caused by <em>Salmonella typhi,</em> a Gram-negative bacterium. A very similar but often less severe disease is caused by the <em>Salmonella</em> serotype <em>paratyphi A in 10% of cases.</em></p>
            <p><em></em></p>
            <p>Humans are the only natural host and reservoir. The infection is transmitted by ingestion of faecally contaminated food or water and through direct contact with infected persons and formites (contaminated items).</p>
            <p><strong>Case Definition:</strong></p>
            <p>Any person with gradual onset of steadily increasing and then persistently high fever, chills, malaise, headache, sore throat, cough, and sometimes abdominal pain and constipation or diarrhoea.</p>
            <p><strong>Clinical features</strong></p>
            <p>The clinical presentation of typhoid fever varies from a mild illness with low grade fever, malaise and dry cough to a severe clinical picture with abdominal discomfort, altered mental status and multiple complications.</p>
            <p>Clinical diagnosis is difficult to make as it is confused with many similar conditions. In the absence of laboratory confirmation, any case of fever of at least 38 °C for 3 or more days is considered suspect if the epidemiological context is suggestive.</p>
            <p>Depending on the dcptrial setting and quality of available medical care, some 5–10% of typhoid patients may develop serious complications, the most frequent being intestinal haemorrhage or peritonitis due to intestinal perforation.</p>
            <p><strong>Laboratory testing</strong></p>
            <p>In Zimbabwe, blood culture samples, stool/rectal swab and bone marrow aspirate have been used to culture for isolation of <em>S typhi</em>. Blood culture is the usual diagnostic test locally with a sensitivity of up to 90% in the first week of onset of fever. Stool and rectal swab cultures yield positive results in up to 40% of the cases.</p>
            <p><strong>Case Management</strong></p>
            <p>More than 90% of patients can be managed at home with oral antimicrobial, minimal nursing care, and close medical follow-up for complications or failure to respond to therapy.</p >
            <p><strong>Antimicrobial therapy for treatment of Typhoid fever</strong></p >
            <p><strong>i) Susceptibility: Fully Sensitive</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>5-7days</p></td></tr >
            </table >
            <p><strong>Alternative Medicines</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>chloramphenicol po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>1g</p></td><td colspan="2"><p>4 times a day</p> </td><td><p>14–21days</p></td></tr>
              <tr><td>or</td><td><p><strong>amoxicillin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>2g</p></td><td colspan="2"><p>3 times a day</p></td><td><p>14days</p></td></tr >
            </table >
            <p><strong>ii)Susceptibility: Multidrug Resistant</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7-14days</p></td></tr>
              <tr><td>or</td><td><p><strong>cefixime po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500-750mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7days</p></td></tr >
            </table >
            <p><strong>Alternative Medicines</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>azithromycin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>1gm</p></td><td colspan="2"><p>Once a day</p></td><td><p>5</p></td></tr>
              <tr><td></td><td><p><strong>Cefixime po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500-750mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7-14</p></td></tr >
            </table >
            <p><strong>iii) Susceptibility: Quinoline Resistant</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>azithromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>250-500mg</p></td><td colspan="2"><p>once a day</p></td><td><p>7</p></td></tr>
              <tr><td>or</td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2gm</p></td><td colspan="2"><p>once a day</p></td><td><p>10-14</p></td></tr >
            </table >
            <p><strong>Alternative Medicines</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>Cefixime po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7-14</p></td></tr >
            </table >
            <p><strong>SEVERE TYPHOID DISEASE</strong></p>
            <p><strong>i) Susceptibility: Fully Sensitive</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>500mg</p></td><td><p>Twice a day</p></td><td><p>7-10</p></td></tr >
            </table >
            <p><strong>Alternative Medicines</strong></p>
            <table>
              <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>chloramphenicol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>14</p></td></tr>
              <tr><td>or</td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>14</p></td></tr>
            </table >
            <p><strong>ii) Susceptibility: Multidrug Resistant</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>10-14</p></td></tr>
              <tr><td>or</td><td><p><strong>Cefixime</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>10-14</p></td></tr >
            </table >
            <p><strong>Alternative Medicines</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>ceftriaxone iv</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>2gm</p></td><td><p>once a day</p></td><td><p>7-14</p></td></tr >
            </table >
            <p><strong>iii) Susceptibility: Quinolone Resistance</strong></p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>ceftriaxone iv</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>2gm</p></td><td><p>once a day</p></td><td><p>7-14</p></td></tr>
              <tr><td>or</td><td><p><strong>azithromycin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>Igm</p></td><td><p>once a day</p></td><td><p>5</p></td></tr >
            </table >
            <p>Dehydration is uncommon in Typhoid fever; however, electrolyte imbalance, e.g. hypoglycaemia, hypokalaemia and hyponatremia frequently occur and need to be corrected using appropriate electrolyte solutions. In cases where intestinal perforation is suspected surgery and parenteral nutrition may be required. In cases of moderate to severe dehydration, follow the guideline for treatment of dehydration.</p>
            <p><strong>A. Treatment of Carriers</strong></p>
            <p>An individual is considered to be a chronic carrier if he or she is asymptomatic and continues to have positive stool or rectal swab cultures for <em>S. typhi</em> a year following recovery from acute illness:</p>
            <table>
              <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
              <tr><td></td><td><p><strong>Ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>4 weeks</p></td></tr >
            </table >
            <p>Ciprofloxacin can be used in children if the benefits outweigh the potential harms.</p>
            <p>And/or:</p>
            <ul>
              <li>Cholecystectomy if lithiasis is present</li>
              <li>Treat schistosomiasis if present</li>
              <li>Vi (virulence) antibody test useful to screen carriers</li>
            </ul >
  
          </span>
      },
      {
        short_title: "Section 11",
        long_title: "Notifiable Diseases",
        content:
          <span>
            <h2>Notifiable Diseases</h2>
            <p>According to the Public Health Act (PHA) Chapter 15:09, there are infectious diseases that have to be immediately notified to health authority in an area by either District Medical Officer, or Provincial Medical Director, or City Health Director.
            These diseases can spread rapidly and cause outbreaks. They need closer monitoring if they are to be controlled. It is important that the health authority knows what action has been taken to control the spreading of the diseases. It is also a requirement that Zimbabwe reports cases and deaths from these diseases to the WHO (World Health Organization).
            While there is a longer list of diseases in the PHA, health workers are encouraged to notify the following using the T1/T2 forms:</p>
            <ol>
              <li>Acute flaccid paralysis (AFP/polio)</li>
              <li>Anthrax</li>
              <li>Brucellosis</li>
              <li>Cholera</li>
              <li>Diphtheria</li>
              <li>Hepatitis (all forms)</li>
              <li>Human Influenza A caused by a new subtype ( e.g. H1N1, H1N5)</li>
              <li>Meningococcal Meningitis</li>
              <li>Noma</li>
              <li>Plague</li>
              <li>Rabies</li>
              <li>SARS</li>
              <li>TB (Tuberculosis) and Leprosy are also notifiable, but they continue to be notified on TB Form A and TB Form B for TB,
        and the Leprosy form for leprosy.</li>
              <li>Trypanosomiasis</li>
              <li>Typhoid</li>
              <li>Typhus</li>
              <li>Viral Haemorrhagic fever (e.g. Ebola, DCPtrial Crimean Congo) </li>
              <li>Yellow fever</li>
              <li>All such other infectious/ communicable dcptrial and events of public health importance as the Minster of Health &amp; Child Care may declare by statutory instrument, to be infectious diseases throughout or in any part of Zimbabwe. These events of public health importance include maternal deaths, disasters such as chemical spillage, floods and others.
        </li>
            </ol>
            <p><strong>How to notify</strong>: Any health worker, including those in private sector, who comes into contact with any of the notifiable diseases. All suspected and laboratory confirmed cases of the above should be notified immediately to the District Medical Officer or City Health Director by the fastest means possible (telephone if available). The notifying health worker should then complete a T1 form in triplicate. These forms can be obtained from the offices of District Medical Officer or City Health Director upon request.</p>
          </span>
      }],
    content:
      <span>
        <h1>Tropical Diseases</h1>
      </span>
  }